newsfilter
← Latest News
GlobeNewswire·

GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress

New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1 data on GBT601 to be highlighted SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) to